Featured Research

from universities, journals, and other organizations

Molecule's role in cancer suggests new combination therapy

Date:
March 1, 2012
Source:
University of Illinois at Chicago
Summary:
Researchers have found that a molecule found at elevated levels in cancer cells seems to protect them from the "cell-suicide" that is usually triggered by chemotherapy or radiation.

Researchers at the University of Illinois at Chicago College of Medicine have found that a molecule found at elevated levels in cancer cells seems to protect them from the "cell-suicide" that is usually triggered by chemotherapy or radiation.

Related Articles


The study, published online in the journal PLoS One on Feb. 29, suggests that two common cancer-fighting strategies may have "tremendous synergy" if used in combination, says Andrei Gartel, UIC associate professor of biochemistry and molecular genetics and medicine and principal investigator on the study.

Damage to a cell's DNA can set in motion a cascade of signals that triggers programmed cell death, or apoptosis. Radiation therapy and many chemotherapy agents target and damage DNA somewhat selectively in rapidly dividing cells, making them useful in fighting cancer. But many cancer cells develop resistance over the course of treatment and block the suicide pathway.

Based on the observation that a protein molecule in cancer cells called FOXM1 is elevated following DNA damage, Gartel and his co-author sought to investigate whether FOXM1 might have a role in protecting cancer cells from apoptosis.

Using human cancer cells that were exposed to either chemicals or radiation to damage DNA, the researchers used a variety of techniques to decrease the levels of FOXM1 in these cells.

"We found a significant increase in DNA-damage-induced apoptosis in cells with diminished levels of FOXM1," Gartel said. The results were the same no matter what caused the DNA damage, or what method the researchers used to reduce FOXM1.

The researchers were able to show that FOXM1 short-circuits apoptosis by suppressing the activity of another protein, JNK, which otherwise stimulates cell death, and by turning up an anti-apoptosis protein called Bcl-2.

Besides the radiation and chemotherapy drugs long used in cancer treatment, a newer class of chemotherapy agents called proteasome inhibitors has been showing promise. All known proteasome inhibitors reduce levels of FOXM1, Gartel said.

By combining standard chemotherapy drugs with proteasome inhibitors -- some of which are already FDA-approved for cancer treatment -- the drugs' effectiveness may be improved, he said.

The study was supported by grants from the National Institutes of Health. Marianna Halasi, a UIC graduate student in biochemistry and molecular genetics, is the first author on the paper.


Story Source:

The above story is based on materials provided by University of Illinois at Chicago. Note: Materials may be edited for content and length.


Journal Reference:

  1. Marianna Halasi, Andrei L. Gartel. Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-Damage. PLoS ONE, 2012; 7 (2): e31761 DOI: 10.1371/journal.pone.0031761

Cite This Page:

University of Illinois at Chicago. "Molecule's role in cancer suggests new combination therapy." ScienceDaily. ScienceDaily, 1 March 2012. <www.sciencedaily.com/releases/2012/03/120301143336.htm>.
University of Illinois at Chicago. (2012, March 1). Molecule's role in cancer suggests new combination therapy. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2012/03/120301143336.htm
University of Illinois at Chicago. "Molecule's role in cancer suggests new combination therapy." ScienceDaily. www.sciencedaily.com/releases/2012/03/120301143336.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins